-- Scott Roberts
MONDAY, June 13 (HealthDay News) -- Potiga (ezogabine) tablets
have been approved by the U.S. Food and Drug Administration to
treat partial epileptic seizures in adults, the agency said
Partial seizures are the most common seizure in people who have
epilepsy, the FDA said in a news release. The agency said Potiga is
the first among a class of drugs called neueronal potassium channel
openers to be sanctioned for epilepsy in the United States.
Potiga may cause "neuro-psychiatric symptoms, including
confusion, hallucinations and psychotic symptoms," which usually
subside within seven days of stopping the drug, the FDA said.
Potiga may also lead to urinary retention, or difficulty fully
emptying the bladder.
And as is the case with other antiepileptic drugs, the agency
said Potiga "may also cause suicidal thoughts or actions in a very
small number of people." Those taking the drug should contact a
physician if they have thoughts of suicide or dying, or worsening
symptoms of anxiety or depression, the FDA warned.
Potiga was developed by North Carolina-based Valeant
Pharmaceuticals North America, and will be distributed by
GlaxoSmithKline, based in Research Triangle, N.C.
To learn more about epilepsy, visit the U.S.
Disease Control and Prevention.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.